Biotech startup machine PureTech has raised a $55 million round to fund the next stage of its evolution, recruiting some big thinkers to help it advance its stable of ventures and develop new technologies.
Last quarter biotech attracted a whopping $1.8 billion in new venture cash, the biggest quarter since 2005.
Today Menlo Park, CA-based Canaan is rolling out a new fund, its 10th, with $675 million to invest in new companies--about a third of which will be devoted to biotech and healthcare.
DNAtrix, at work on viral treatment that selectively infects brain cancer cells, picked up $20 million in venture cash, funds the company said will help speed its candidate into late-stage study.
While Atlas Venture was busy putting together a syndicate for Raze in Cambridge, MA, the venture group was also engaged in hatching a $32 million round across the Atlantic in the scientific hotbed of Cambridge, U.K. Atlas partnered with SV Life Sciences and three corporate venture arms--Novartis Venture Fund, GlaxoSmithKline's SR One and Astellas Venture Management--to back Bicycle Therapeutics.
With report after report finding flaws in the data security practices of healthcare and life science organizations, Exostar has decided to accelerate its expansion into the sector. And the company has snagged funding from the Merck Global Health Innovation Fund to support its plans.
After more than 25 years in drug development that culminated in a corner office at Calistoga Pharmaceuticals, Carol Gallagher decamped for the venture world last year, and now she has accepted a position at New Enterprise Associates to help nurture the next generation of disruptive biotechs.
Rescued from Pfizer's sweeping R&D cuts, Levicept's lead drug is a protein with promise in chronic pain, and the biotech has raised $15.7 million in venture and grant funding to follow through on its potential.
It's better to be lucky than smart, but to be among the best life sciences investors it helps to be both. We've compiled a list of public company investors who have managed to outperform the...
Closely allied with Eli Lilly, TVM Capital Life Sciences has bumped up its latest fund past the $200 million mark with plans to bankroll up to 15 build-to-buy drug development projects.